礼来公司注册了3M公司探察性疱疹药物的全球权利
&nbps;&nbps;&nbps;&nbps;NEW YORK (Reuters Health) - Eli Lilly & Co. has acquired the worldwide rights to a late-stage genital herpes treatment developed by St. Paul-based Minnesota Mining and Manufacturing Co. (3M), the companies announced on Tuesday.
&nbps;&nbps;&nbps;&nbps;The drug, generically known as resiquimod, is part of a new family of immune response modifier molecules developed by 3M Pharmaceuticals, the companies said. The drug is currently being evaluated in a number of ongoing phase II and phase III trials for recurrent genital herpes.
&nbps;&nbps;&nbps;&nbps;Although 3M handles the marketing of Aldara (imiquimod), an approved genital warts treatment of the same class as resiquimod, a company spokesman told Reuters Health that a number of factors led to the decision to partner out the investigational product.
&nbps;&nbps;&nbps;&nbps;"We've got good coverage of the dermatology and gynecological markets," he said. However, "Lilly is a real strong leader in infectious diseases, they have great coverage in the primary care physician market and they've got a proven track record of marketing blockbuster drugs. "
&nbps;&nbps;&nbps;&nbps;"They're an ideal partner for us," he said.
&nbps;&nbps;&nbps;&nbps;Under the terms of the deal, 3M will receive a $100 million upfront fee in the fourth quarter for the rights to the product, as well milestones, royalties and an option to co-promote the drug to certain US customer groups.
&nbps;&nbps;&nbps;&nbps;3M will also continue to be responsible for all remaining clinical development and regulatory efforts for resiquimod in the US. International regulatory filings would be handled jointly, with primary responsibility falling to Lilly.
&nbps;&nbps;&nbps;&nbps;The 3M spokesman said that the company expects to file resiquimod with the US Food and Drug Administration in 2004, with a European filing shortly thereafter.
&nbps;&nbps;&nbps;&nbps;Additional terms of the deal, which is expected to close next month, remain undisclosed.
&nbps;&nbps;&nbps;&nbps;During Tuesday afternoon trading on the New York Stock Exchange, shares of Indianapolis, Indiana-based Lilly were down 0.03 at 76.87, while shares of 3M were up 0.76 at 92.43., 百拇医药
&nbps;&nbps;&nbps;&nbps;The drug, generically known as resiquimod, is part of a new family of immune response modifier molecules developed by 3M Pharmaceuticals, the companies said. The drug is currently being evaluated in a number of ongoing phase II and phase III trials for recurrent genital herpes.
&nbps;&nbps;&nbps;&nbps;Although 3M handles the marketing of Aldara (imiquimod), an approved genital warts treatment of the same class as resiquimod, a company spokesman told Reuters Health that a number of factors led to the decision to partner out the investigational product.
&nbps;&nbps;&nbps;&nbps;"We've got good coverage of the dermatology and gynecological markets," he said. However, "Lilly is a real strong leader in infectious diseases, they have great coverage in the primary care physician market and they've got a proven track record of marketing blockbuster drugs. "
&nbps;&nbps;&nbps;&nbps;"They're an ideal partner for us," he said.
&nbps;&nbps;&nbps;&nbps;Under the terms of the deal, 3M will receive a $100 million upfront fee in the fourth quarter for the rights to the product, as well milestones, royalties and an option to co-promote the drug to certain US customer groups.
&nbps;&nbps;&nbps;&nbps;3M will also continue to be responsible for all remaining clinical development and regulatory efforts for resiquimod in the US. International regulatory filings would be handled jointly, with primary responsibility falling to Lilly.
&nbps;&nbps;&nbps;&nbps;The 3M spokesman said that the company expects to file resiquimod with the US Food and Drug Administration in 2004, with a European filing shortly thereafter.
&nbps;&nbps;&nbps;&nbps;Additional terms of the deal, which is expected to close next month, remain undisclosed.
&nbps;&nbps;&nbps;&nbps;During Tuesday afternoon trading on the New York Stock Exchange, shares of Indianapolis, Indiana-based Lilly were down 0.03 at 76.87, while shares of 3M were up 0.76 at 92.43., 百拇医药